Cromos Pharma, where the patients are

Drug Sponsors

TNI BioTech forms new subsidiary Cytocom

Thursday, March 6, 2014 03:58 PM

TNI BioTech, a biotech company working on chronic, life-threatening diseases, has formed a new subsidiary, Cytocom, for developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).

More... »

CRF Health eCOA webinar series

Xenetic Biosciences opens headquarters, R&D facility

Wednesday, March 5, 2014 01:19 PM

Xenetic Biosciences, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, has opened its new corporate headquarters and R&D facility in Lexington, Mass. Xenetic relocated its global headquarters to Lexington from London.

More... »

Human Longevity launched to promote healthy aging

Wednesday, March 5, 2014 01:13 PM

Human Longevity (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high-performance human life span, has been launched by co-founders J. Craig Venter, Ph.D., Robert Hariri, M.D., Ph.D., and Peter H. Diamandis, M.D.

More... »

Bayer to acquire Dihon Pharmaceutical in China

Thursday, February 27, 2014 12:30 PM

Bayer plans to acquire Dihon Pharmaceutical Group, a privately held pharmaceutical company based in Kunming Yunnan, China, specializing primarily in over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products.

More... »

Emergent BioSolutions completes acquisition of Cangene

Monday, February 24, 2014 10:13 AM

Emergent BioSolutions, a specialty pharmaceutical company offering specialized products to healthcare providers and governments, has completed its acquisition of Cangene for $222 million in cash. After payment by Cangene of transaction related costs, Emergent expects to receive approximately $40 million of cash from Cangene in connection with closing. The completion of the acquisition follows the successful conclusion of all closing conditions, including approval by the Ontario Superior Court of Justice and a positive vote by Cangene shareholders at a special shareholder meeting held Feb. 12. The transaction is consistent with Emergent’s growth plan in that it diversifies the company’s revenue mix, adds commercial product sales and contributes to earnings growth.

More... »

Actavis to acquire Forest Laboratories for $25 billion

Tuesday, February 18, 2014 10:39 AM

Dublin-based Actavis has agreed to acquire Forest Laboratories of New York for a combination of cash and equity valued at approximately $25 billion.

More... »

Report: Strong Q4 M&A momentum expected to continue into 2014

Wednesday, February 12, 2014 01:44 PM

Pharmaceutical and life sciences (PLS) merger and acquisition volume and value increased in the fourth quarter of 2013, finishing the year for deal activity on a high note,according to Pharmaceutical and Life Sciences Deals Insights Quarterly, a quarterly analysis of M&A trends and outlook for the PLS sector issued by PwC. PwC’s Health Industries Group is an advisor to public and private organizations across the health industries.

More... »

Mallinckrodt to acquire Cadence Pharmaceuticalsfor $1.3 billion

Wednesday, February 12, 2014 01:26 PM

A subsidiary of Mallinckrodt, a global specialty pharmaceuticals company, will acquire Cadence Pharmaceuticals, and will commence a tender offer to acquire all outstanding shares for $14 per share in cash, or approximately $1.3 billion, a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share.

More... »

Mast Therapeutics to acquire Aires Pharmaceuticals

Monday, February 10, 2014 11:35 AM

Mast Therapeutics has entered into a definitive agreement to acquire Aires Pharmaceuticals, a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has Orphan Drug status with the FDA and the EMA for the treatment of pulmonary arterial hypertension.

More... »

Pelican Products acquires Cool Logistics

Friday, February 7, 2014 02:09 PM

Behrman Capital, a private equity investment firm based in New York and San Francisco, announced that its portfolio company Pelican Products, a design and manufacturer of high-performance protective case solutions and advanced portable lighting systems, has acquired U.K.-based Cool Logistics, a provider of temperature controlled packaging solutions. Financial terms of the transaction have not been disclosed.

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs